Pediatric Gastroenterology, Hepatology & Nutrition

The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition (대한소아소화기영양학회)
권호 표지
DOI QR코드

DOI QR Code

Recent Advances in the Clinical Application of Next-Generation Sequencing

  • Received : 2020.12.04
  • Accepted : 2020.12.08
  • Published : 2021.01.15
Download PDF
⟨ Previous Next ⟩

Abstract

Next-generation sequencing (NGS) technologies have changed the process of genetic diagnosis from a gene-by-gene approach to syndrome-based diagnostic gene panel sequencing (DPS), diagnostic exome sequencing (DES), and diagnostic genome sequencing (DGS). A priori information on the causative genes that might underlie a genetic condition is a prerequisite for genetic diagnosis before conducting clinical NGS tests. Theoretically, DPS, DES, and DGS do not require any information on specific candidate genes. Therefore, clinical NGS tests sometimes detect disease-related pathogenic variants in genes underlying different conditions from the initial diagnosis. These clinical NGS tests are expensive, but they can be a cost-effective approach for the rapid diagnosis of rare disorders with genetic heterogeneity, such as the glycogen storage disease, familial intrahepatic cholestasis, lysosomal storage disease, and primary immunodeficiency. In addition, DES or DGS may find novel genes that that were previously not linked to human diseases.

Keywords

References

  1. Lee ES, Cho AR, Ki CS. Identification of SLC26A3 mutations in a Korean patient with congenital chloride diarrhea. Ann Lab Med 2012;32:312-5. https://doi.org/10.3343/alm.2012.32.4.312
  2. Choi M, Scholl UI, Ji W, Liu T, Tikhonova IR, Zumbo P, et al. Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. Proc Natl Acad Sci U S A 2009;106:19096-101. https://doi.org/10.1073/pnas.0910672106
  3. Adams DR, Eng CM. Next-generation sequencing to diagnose suspected genetic disorders. N Engl J Med 2018;379:1353-62. https://doi.org/10.1056/NEJMra1711801
  4. Kim JH, Kang E, Heo SH, Kim GH, Jang JH, Cho EH, et al. Diagnostic yield of targeted gene panel sequencing to identify the genetic etiology of disorders of sex development. Mol Cell Endocrinol 2017;444:19-25. https://doi.org/10.1016/j.mce.2017.01.037
  5. Kim YM, Lee YJ, Park JH, Lee HD, Cheon CK, Kim SY, et al. High diagnostic yield of clinically unidentifiable syndromic growth disorders by targeted exome sequencing. Clin Genet 2017;92:594-605. https://doi.org/10.1111/cge.13038
  6. Nam SH, Hong YB, Hyun YS, Nam E, Kwak G, Hwang SH, et al. Identification of genetic causes of inherited peripheral neuropathies by targeted gene panel sequencing. Mol Cells 2016;39:382-8. https://doi.org/10.14348/MOLCELLS.2016.2288
  7. Ko A, Youn SE, Kim SH, Lee JS, Kim S, Choi JR, et al. Targeted gene panel and genotype-phenotype correlation in children with developmental and epileptic encephalopathy. Epilepsy Res 2018;141:48-55. https://doi.org/10.1016/j.eplepsyres.2018.02.003
  8. Rim JH, Kim SH, Hwang IS, Kwon SS, Kim J, Kim HW, et al. Efficient strategy for the molecular diagnosis of intractable early-onset epilepsy using targeted gene sequencing. BMC Med Genomics 2018;11:6. https://doi.org/10.1186/s12920-018-0320-7
  9. Han JY, Jang JH, Park J, Lee IG. Targeted next-generation sequencing of Korean patients with developmental delay and/or intellectual disability. Front Pediatr 2018;6:391. https://doi.org/10.3389/fped.2018.00391
  10. Rim JH, Lee ST, Gee HY, Lee BJ, Choi JR, Park HW, et al. Accuracy of next-generation sequencing for molecular diagnosis in patients with infantile nystagmus syndrome. JAMA Ophthalmol 2017;135:1376-85. https://doi.org/10.1001/jamaophthalmol.2017.4859
  11. Lee J, Ha S, Lee ST, Park SG, Shin S, Choi JR, et al. Next-generation sequencing in Korean children with autism spectrum disorder and comorbid epilepsy. Front Pharmacol 2020;11:585. https://doi.org/10.3389/fphar.2020.00585
  12. Ewans LJ, Schofield D, Shrestha R, Zhu Y, Gayevskiy V, Ying K, et al. Whole-exome sequencing reanalysis at 12 months boosts diagnosis and is cost-effective when applied early in Mendelian disorders. Genet Med 2018;20:1564-74. https://doi.org/10.1038/gim.2018.39
  13. Yang Y, Muzny DM, Reid JG, Bainbridge MN, Willis A, Ward PA, et al. Clinical whole-exome sequencing for the diagnosis of mendelian disorders. N Engl J Med 2013;369:1502-11. https://doi.org/10.1056/NEJMoa1306555
  14. Yang Y, Muzny DM, Xia F, Niu Z, Person R, Ding Y, et al. Molecular findings among patients referred for clinical whole-exome sequencing. JAMA 2014;312:1870-9. https://doi.org/10.1001/jama.2014.14601
  15. Lee H, Deignan JL, Dorrani N, Strom SP, Kantarci S, Quintero-Rivera F, et al. Clinical exome sequencing for genetic identification of rare Mendelian disorders. JAMA 2014;312:1880-7. https://doi.org/10.1001/jama.2014.14604
  16. Retterer K, Juusola J, Cho MT, Vitazka P, Millan F, Gibellini F, et al. Clinical application of whole-exome sequencing across clinical indications. Genet Med 2016;18:696-704. https://doi.org/10.1038/gim.2015.148
  17. Meienberg J, Bruggmann R, Oexle K, Matyas G. Clinical sequencing: is WGS the better WES? Hum Genet 2016;135:359-62. https://doi.org/10.1007/s00439-015-1631-9
  18. Marshall CR, Bick D, Belmont JW, Taylor SL, Ashley E, Dimmock D, et al. The Medical Genome Initiative: moving whole-genome sequencing for rare disease diagnosis to the clinic. Genome Med 2020;12:48. https://doi.org/10.1186/s13073-020-00748-z
  19. Lionel AC, Costain G, Monfared N, Walker S, Reuter MS, Hosseini SM, et al. Improved diagnostic yield compared with targeted gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic test. Genet Med 2018;20:435-43. https://doi.org/10.1038/gim.2017.119
  20. Ostrander BEP, Butterfield RJ, Pedersen BS, Farrell AJ, Layer RM, Ward A, et al. Whole-genome analysis for effective clinical diagnosis and gene discovery in early infantile epileptic encephalopathy. NPJ Genom Med 2018;3:22. https://doi.org/10.1038/s41525-018-0061-8
  21. Brewer MH, Chaudhry R, Qi J, Kidambi A, Drew AP, Menezes MP, et al. Whole genome sequencing identifies a 78 kb insertion from chromosome 8 as the cause of Charcot-Marie-Tooth neuropathy CMTX3. PLoS Genet 2016;12:e1006177. https://doi.org/10.1371/journal.pgen.1006177
  22. Scocchia A, Wigby KM, Masser-Frye D, Del Campo M, Galarreta CI, Thorpe E, et al. Clinical whole genome sequencing as a first-tier test at a resource-limited dysmorphology clinic in Mexico. NPJ Genom Med 2019;4:5. https://doi.org/10.1038/s41525-018-0076-1
  23. Vaz-Drago R, Custódio N, Carmo-Fonseca M. Deep intronic mutations and human disease. Hum Genet 2017;136:1093-111. https://doi.org/10.1007/s00439-017-1809-4
  24. Di Scipio M, Tavares E, Deshmukh S, Audo I, Green-Sanderson K, Zubak Y, et al. Phenotype driven analysis of whole genome sequencing identifies deep intronic variants that cause retinal dystrophies by aberrant exonization. Invest Ophthalmol Vis Sci 2020;61:36.
  25. Larrue R, Chamley P, Bardyn T, Lionet A, Gnemmi V, Cauffiez C, et al. Diagnostic utility of whole-genome sequencing for nephronophthisis. NPJ Genom Med 2020;5:38. https://doi.org/10.1038/s41525-020-00147-8

Cited by

  1. Evaluating, Filtering and Clustering Genetic Disease Cohorts Based on Human Phenotype Ontology Data with Cohort Analyzer vol.11, pp.8, 2021, https://doi.org/10.3390/jpm11080730
  2. Design and Validation of a Custom NGS Panel Targeting a Set of Lysosomal Storage Diseases Candidate for NBS Applications vol.22, pp.18, 2021, https://doi.org/10.3390/ijms221810064